Pravastatin Reduces Acute Phase Response of Zoledronic Acid
Status:
Not yet recruiting
Trial end date:
2022-04-01
Target enrollment:
Participant gender:
Summary
Acute phase response (APR) is one of the most common adverse events in osteoporosis with
zoledronic acid treatment. It's reported that this reaction is related to the blockade of the
mevalonate pathway, leading to isopentenyl pyrophosphate (IPP) accumulation. And the latter
can active γδT cells in the circulation, resulting in inflammatory cytokine release. Statins
can inhibit the conversion of HMG-CoA to mevalonate that may reduce the accumulation of IPP.
Therefore, it is possible that statins can be taken in advance to reduce APR caused by
zoledronic acid infusion.